The Modernization of HIV Laws in Nevada; Changing Legislature

The Modernization of HIV Laws in Nevada; Changing Legislature

Andre Wade provides an overview of how the state of Nevada addressed a structural barrier to HIV prevention and care by modernizing its HIV duty to warn laws. HIV criminalization laws, a.k.a. duty to warn, were established across the nation in the early 1990’s as part of the 1990 Ryan White CARE Act – requiring states to certify that they had adequate laws in place to prosecute individuals who knowingly exposed another person to HIV. These outdated and discriminatory laws aided in increasing HIV stigma, hindered disclosure of HIV status, and created barriers to access to HIV prevention and care services. 

Watch all recorded videos from our Structural Interventions for HIV Prevention and Care Virtual Institute.

April 2022 Seminar on PrEP Financing and Logistics

April 2022 Seminar on PrEP Financing and Logistics

April 28, 2022

PrEP Financing Resources

PrEP Financing Resources

Resources and updates from the CAPTC’s PrEP Financing Learning Collaborative to support clinics and navigators with PrEP financing questions.

Includes information on California’s PrEP Assistance Program (PrEP-AP), other resources for covering the cost of PrEP, billing resources, and other coverage information for patients and providers.

Ending the HIV Epidemic

Opt-Out ED Screening for HIV, HCV, and Syphilis—Dear Colleague Letter from CDPH

Opt-Out ED Screening for HIV, HCV, and Syphilis—Dear Colleague Letter from CDPH

March 28, 2022: Emergency departments (EDs) are uniquely positioned to identify people with syphilis, HIV, and hepatitis C who otherwise might remain undiagnosed. The California Department of Public Health (CDPH) recommends that EDs consider implementing routine opt-out testing for syphilis, HIV, and hepatitis C.

Identification and immediate treatment through the ED may have the added benefit of furthering health equity for those disproportionately affected by these infections

harm reduction supplies

STI Expert Hour Webinar: Why the Dose Matters: PrEP Strategies for HIV

January 11, 2022

Presented by Katherine Yang, PharmD, MPH

Pre-Exposure prophylaxis (PrEP) has been shown to be safe and effective in reducing HIV infection. With recent updates in PrEP, many options are available, and selection of the best regimen is the key to success. The purpose of this webinar is to review the pharmacologic basis for drug dosing and outline gaps and challenges in management.

Learning objectives

  1. Review the key pharmacokinetic and pharmacodynamic properties of emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, and cabotegravir.
  2. Identify patients who may be appropriate for Daily vs. Event-Driven PrEP.
  3. Review key side effects of PrEP and potential strategies for management.
  4. Describe the role of adherence on PrEP effectiveness.

2021 PrEP Clinical Practice Guideline – Clinical Providers’ Supplement

2021 PrEP Clinical Practice Guideline – Clinical Providers’ Supplement

Updated Clinical Providers’ Supplement accompanying the 2021 PrEP Clinical Practice Guideline.

Updates for 2021 include:

  • Checklist updated to include Descovy, 2-1-1 Truvada for MSM, and cabotegravir
  • Added PrEP with intramuscular cabotegravir (CAB) injections (conditional on FDA approval) recommendation for HIV prevention in adults 
  • Added information about Descovy and cabotegravir to Patient Information Sheets
CDC logo

2021 PrEP Clinical Practice Guideline

2021 PrEP Clinical Practice Guideline

Comprehensive information for the use of antiretroviral preexposure prophylaxis (PrEP) to prevent acquiring HIV infection.

Updates for 2021 include:

  • A recommendation to inform all sexually active adults and adolescents about PrEP
  • PrEP with intramuscular cabotegravir (CAB) injections (conditional on FDA approval) is recommended for HIV prevention in adults reporting sexual behaviors that place them at substantial ongoing risk of HIV exposure and acquisition.

Also view the updated PrEP Providers Supplement for 2021.

Comprehensive information for the use of antiretroviral preexposure prophylaxis (PrEP) to prevent acquiring HIV infection.

Updates for 2021 include:

  • A recommendation to inform all sexually active adults and adolescents about PrEP
  • PrEP with intramuscular cabotegravir (CAB) injections (conditional on FDA approval) is recommended for HIV prevention in adults reporting sexual behaviors that place them at substantial ongoing risk of HIV exposure and acquisition.

Also view the updated PrEP Providers Supplement for 2021.

Perinatal HIV and Congenital Syphilis—Dear Colleague Letter from CDPH

Perinatal HIV and Congenital Syphilis—Dear Colleague Letter from CDPH

November 16, 2021: CDPH is asking for assistance in responding to concerning increases in congenital syphilis and perinatal HIV in California. Perinatal HIV transmission and congenital syphilis can be prevented with timely testing and treatment. A common risk factor, however, is receiving late or no prenatal care.

CDPH requests your assistance to implement the following policies and best practices to Screen, Treat and Prevent, and Prepare for perinatal transmissions

California Department of Public Health Logo

PrEP Provider Pocket Card

PrEP Provider Pocket Card

Clinical PrEP essentials and key messages available in an easily accessible pocket card. From SF CBA and the San Francisco Health Network. 

person holding blue pills

Social Determinants of Health and HIV

An understanding of social determinants is essential to the implementation of effective HIV treatment or prevention interventions. This engaging and informative one-hour online course, based on our popular two-day instructor-led training, provides an introduction to social determinants and HIV.

Learn more and register